Where does Idorsia Pharmaceuticals Ltd rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Idorsia Pharmaceuticals Ltd ranks #4,563 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Idorsia Pharmaceuticals Ltd hold?

Idorsia Pharmaceuticals Ltd holds 77 US utility patents granted between 2017 and 2025, spanning 14 technology areas.

What is Idorsia Pharmaceuticals Ltd's Innovation Score?

Idorsia Pharmaceuticals Ltd has an Innovation Score of 49.3 out of 100 (top 15% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Idorsia Pharmaceuticals Ltd's patent grant rate increasing or decreasing?

Idorsia Pharmaceuticals Ltd's recent grant velocity is +31% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Idorsia Pharmaceuticals Ltd's patents?

Idorsia Pharmaceuticals Ltd's patents average 22.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Idorsia Pharmaceuticals Ltd patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Idorsia Pharmaceuticals Ltd

Q: What technology areas does Idorsia Pharmaceuticals Ltd focus on?

Idorsia Pharmaceuticals Ltd's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 71 patents. Grants appear in 14 CPC subclasses total.

USPTO PatentsView assignee record - 77 granted patents across 14 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Idorsia ranks #4,563 of 49,997 tracked US assignees by granted-patent volume, with 77 patents across 14 technology areas.

#4,563
of 49,997 US assignees by volume: Top 15%
by Innovation Score (49.3/100): 22.4
avg claims per patent: +31%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4563 · Foreign Corporation #4,563 · 77 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 77 grants
TOP-DECILE #4,563/49,997
PHOTO-FINISH GE Oil & Gas…
CPC-FOCUS A61P · 14 areas
INNOV-PAR 49.3/100
CLAIMS-DENSE 22.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +31% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: GE Oil & Gas Pressure Control LP (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Seereal · near

49
Goertek Technology · near

49
Idorsia Pharmaceutic… · this assignee

49
Nevro · near

49
Nuscale Power · near

49
3D Lighting… · lowest

7

What this shows Idorsia's Innovation Score is 49.3/100 (top 15% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Idorsia's grants concentrate

Idorsia Pharmaceuticals Ltd is a focused PatentsView assignee: 14 CPC subclasses with 92.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (12 grants) versus a trough of 4 in 2024. By volume, Idorsia sits between GE Oil & Gas Pressure Control LP and Loewenstein Medical Technology S.A..

Idorsia's three-year grant acceleration

From 2019–2021 to 2022–2024, Idorsia Pharmaceuticals Ltd moved from 22 to 25 grants (1.14x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

GE Oil & Gas Pres…

77
GLO AB

77
Hangzhou Sanhua R…

77
Hunan Brunp Recyc…

77
Isis Innovation

77
J S T MFG

77
L3

77
Loewenstein Medic…

77
Idorsia Pharmaceu… ◀

77

What this shows Idorsia holds 77 patents at rank #4,563, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Idorsia

By rank, the assignees closest to #4,563 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Idorsia's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Idorsia, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (49 here).

Nuscale Power, LLC 49 Nevro Corp. 49 Goertek Technology Co., Ltd. 49 Seereal Technologies S.A. 49

Similar claim depth

Nearest assignees by average claims per patent (22.4 here).

NthDegree Technologies Worldwide Inc 22.4 avg Cylance Inc. 22.4 avg Taris Biomedical LLC 22.4 avg iBiquity Digital Corporation 22.4 avg

Idorsia's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 15% higher than 85% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Idorsia Pharmaceuticals Ltd patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	8	10.4%
2018	12	15.6%
2019	9	11.7%
2020	5	6.5%
2021	8	10.4%
2022	11	14.3%
2023	10	13.0%
2024	4	5.2%
2025partial year	10	13.0%

Which technologies does Idorsia Pharmaceuticals Ltd patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 71

C07D - Heterocyclic Compounds 63

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 38

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 19

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 11

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 8

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07C - Acyclic OR Carbocyclic Compounds 1

C08B - POLYSACCHARIDES; Derivatives Thereof 1

F04B - Positive-displacement Machines FOR LIQUIDS; Pumps 1

A61B - DIAGNOSIS; SURGERY; Identification 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 1

Top 14 of 14 technology areas

Where it ranks

Overall rank by patents

#4,563

of 49,997 tracked assignees

Innovation Score

49.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Idorsia Pharmaceuticals Ltd's patent record in context - here's where to go next.

Idorsia Pharmaceuticals Ltd's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,563 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Idorsia Pharmaceuticals Ltd against GE Oil & Gas Pressure Control LP, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.